A randomized, controlled trial of the effect of rilpivirine versus efavirenz on cardiovascular risk in healthy volunteers | Zendy

Samir K. Gupta | Zendy; James E. Slaven | Zendy; Lisa M. Kamendulis | Zendy; Ziyue Liu | Zendy

Open Access

A randomized, controlled trial of the effect of rilpivirine versus efavirenz on cardiovascular risk in healthy volunteers

Author(s) -

Samir K. Gupta,

James E. Slaven,

Lisa M. Kamendulis,

Ziyue Liu

Publication year - 2015

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkv195

Subject(s) - rilpivirine , efavirenz , medicine , reverse transcriptase inhibitor , randomized controlled trial , human immunodeficiency virus (hiv) , sida , virology , antiretroviral therapy , viral load , viral disease

The HIV NNRTI rilpivirine is being evaluated as a possible agent for HIV pre-exposure prophylaxis. We have recently shown that the NNRTI efavirenz may impair endothelial function assessed as flow-mediated dilation (FMD), but whether this impairment is also found with rilpivirine is unknown. We sought to compare cardiovascular risk profiles between efavirenz and rilpivirine in healthy volunteers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research